Morphocell Technologies

Montreal, Canada Founded: 2018 • Age: 8 yrs
Engineered liver tissues are developed for liver disease treatments.
Request Access

About Morphocell Technologies

Morphocell Technologies is a company based in Montreal (Canada) founded in 2018.. Morphocell Technologies has raised $50 million across 3 funding rounds from investors including CQDM, Invest Quebec and CDP Venture Capital. Morphocell Technologies offers products and services including ReLiver. Morphocell Technologies operates in a competitive market with competitors including NGM Biopharmaceuticals, Avidity Biosciences, Nimbus Therapeutics, Univercells and Sutro Biopharma, among others.

  • Headquarter Montreal, Canada
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $50 M (USD)

    in 3 rounds

  • Latest Funding Round
    $10 M (USD), Series A

    Dec 01, 2025

  • Investors
    CQDM

    & 3 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Morphocell Technologies

Morphocell Technologies offers a comprehensive portfolio of products and services, including ReLiver. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Develops tissue for treating liver diseases via advanced engineering.

People of Morphocell Technologies
Headcount 1-10
Employee Profiles 5
Employee Profiles
People
Vincent Ling
Chief Business Officer
People
Massimiliano Paganelli
Co-Founder, President and Chief Executive Officer
People
Calley Hirsch
Vice President, Preclinical Development
People
Panos C.
Chief Development Officer

Unlock access to complete

Teams

Funding Insights of Morphocell Technologies

Morphocell Technologies has successfully raised a total of $50M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series A — $10.0M
  • First Round
  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2025 Amount Series A - Morphocell Technologies Valuation Invest Quebec , CDP Venture Capital
Feb, 2024 Amount Series A - Morphocell Technologies Valuation Genson Capital
Jul, 2021 Amount Seed - Morphocell Technologies Valuation CQDM
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Morphocell Technologies

Morphocell Technologies has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include CQDM, Invest Quebec and CDP Venture Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
CQDM is focused on facilitating biopharma innovation through funding.
Founded Year Domain Location
Venture capital and fund of funds focused on multiple sectors
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Morphocell Technologies

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Morphocell Technologies

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Morphocell Technologies Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Morphocell Technologies

Morphocell Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Avidity Biosciences, Nimbus Therapeutics, Univercells and Sutro Biopharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Biologics are developed for cardio-metabolic and liver diseases.
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
domain founded_year HQ Location
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Morphocell Technologies

Frequently Asked Questions about Morphocell Technologies

When was Morphocell Technologies founded?

Morphocell Technologies was founded in 2018 and raised its 1st funding round 3 years after it was founded.

Where is Morphocell Technologies located?

Morphocell Technologies is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.

Is Morphocell Technologies a funded company?

Morphocell Technologies is a funded company, having raised a total of $50M across 3 funding rounds to date.

What does Morphocell Technologies do?

Morphocell Technologies was founded in 2018 in Montreal, Canada, within the biotechnology sector. ReLiver, an engineered liver tissue, is utilized to create an implantable device for acute-on-chronic liver failure, an extracorporeal bio-artificial liver device, and in vitro assays for drug discovery. Operations focus on advancing these medical technologies to address liver-related conditions.

Who are the top competitors of Morphocell Technologies?

Morphocell Technologies's top competitors include Sutro Biopharma, Nimbus Therapeutics and Avidity Biosciences.

What products or services does Morphocell Technologies offer?

Morphocell Technologies offers ReLiver.

Who are Morphocell Technologies's investors?

Morphocell Technologies has 4 investors. Key investors include CQDM, Invest Quebec, CDP Venture Capital, and Genson Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available